Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy

Inclusion Criteria

• •Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care
• •Subject is not pregnant or breast feeding, and cannot become pregnant within 30 days after the end of treatment
• •Female subject of child bearing potential must be willing to use, in combination with her partner, 2 forms highly effective contraception during treatment and for 1 month after the end of treatment
• •Diagnosis of any stage of multiple myeloma based on standard criteria as follows:
• •* Major criteria
• •1. Plasmacytomas on tissue biopsy
• •2. Bone marrow plasmacytosis (\> 30% plasma cells)
• •3. Monoclonal immunoglobulin spike on serum electrophoresis (immunoglobin G \[IgG\] \> 3.5 G/dL or immunoglobin A \[IgA\] \> 2.0 G/dL) or kappa or lambda light chain excretion \> 1 G/day on 24 hour urine protein electrophoresis
• •* Minor criteria
• •1. Bone marrow plasmacytosis (10 to 30% plasma cells)
• •2. Monoclonal immunoglobulin present but of lesser magnitude than given under major criteria
• •3. Lytic bone lesions
• •4. Normal immunoglobin M (IgM) \< 50 mg/dL, IgA \< 100 mg/dL, or IgG \< 600 mg/dL
• •* Any of the following sets of criteria will confirm the diagnosis of multiple myeloma:
• •* Any two of the major criteria
• •* Major criterion 1 plus minor criterion b, c, or d
• •* Major criterion 3 plus minor criterion a or c
• •* Minor criteria a, b and c or a, b and d
• •Karnofsky performance status \>= 50
• •Platelet count =\< 50 x 10\^9/L untransfused of at least 2 weeks duration, secondary to prior chemotherapy. If there is a platelet count of \> or = 50 x 10(9)/L after a transfusion, that value will be discounted.
• •This may include a combination regimen including lenalidomide; these regimens will include dexamethasone, cyclophosphamide, etoposide, cisplatin (DCEP), Velcade with Doxil, Cytoxan and/or lenalidomide; patients who have thrombocytopenia (CIT) from lenalidomide or from radiation therapy alone will not be allowed
• •Calculated or measured creatinine clearance \>= 30 mL/min